Howard Liebman, MD

Since 1999, Dr. Liebman has authored or co-authored over 100 medical articles and chapters and has led well over a hundred lectures across the United States, South America, Europe, and Japan on a variety of medical topics.

He has also been the recipient of millions of dollars in research grants, reviewed a number of medical journals, and is a former Chair of the Massachusetts Governor’s Task Force subcommittee on experimental therapies and clinical trials for AIDS.

In addition to his academic responsibilities, Dr. Liebman is an attending staff member of the LAC+USC Medical Center, the USC/Norris Comprehensive Cancer Center and the Keck Hospital of USC.

Dr. Liebman is on the forefront of research in thrombotic and hemorrhagic disorders. His lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, arterial thrombosis, and thrombosis associated with cancer chemotherapy. Additional studies are elucidating the role of prothrombotic defects in developing osteonecrosis. He has also been the principle investigator on a number of clinical trials in the management of immune thrombocytopenia. His research group has made important discoveries on the role of infectious agents in the development of immune thrombocytopenia. Dr. Liebman is also internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy and has served on the Cancer and Thrombosis Guideline Committee of the American Society of Clinical Oncology.